Takeda Pharmaceutical's new dengue vaccine Qdenga received approval in India. The vaccine is expected to launch commercially in early 2027....

Health insurance covers childhood illnesses and their treatments effectively. Vaccination support is a key preventive care strategy for fam...

India's first dengue vaccine is nearing rollout as a study maps circulating virus strains. All four dengue serotypes are now circulating si...

India's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in ...

School Assembly News Headlines Today July 21: Parliament faced disruptions as opposition demanded discussions on alleged paper leaks. Heavy...

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individua...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological ...

India started its inaugural phase 3 clinical trial for the DengiAll dengue vaccine, developed by Panacea Biotec. The trial will include 10,...

The Indian Council of Medical Research (ICMR) and Panacea Biotec have launched the first phase three clinical trial for an indigenous dengu...

An expert committee recommended continuation of phase-II clinical trial of Serum Institute of India's vaccine against dengue after successf...

Takeda Pharmaceuticals' dengue vaccine assumes significance since the first vaccine ever licensed for dengue, developed by French drugmaker...

Yesterday, the Philippines government ordered an investigation into the immunisation of more than 7.3 lakh children with the company's deng...

This is the Mumbai-based company’s second collaboration focussed on the mosquito-borne virus, the first being its pact to develop a botanic...

Sun Pharma will fund and support further development of the vaccine candidate and existing ICGEB knowhow and patents.

The ICGEB plans a larger vaccine trial on monkeys in America; the full-fledged human trial after that could cost more than Rs 100 crore.

Country Head, Sanofi Pasteur, Stephan Barth, said dengue is a serious health concern in India, causing a significant but under-reported bur...

The study showed that 87% of Indian adults in trial were positive to dengue at enrolment, confirming the significant endemic nature of the ...